K-RAS mutations indicating primary resistance to crizotinib in ALK-rearranged adenocarcinomas of the lung: Report of two cases and review of the literature

Lung Cancer

Volumn 93, Issue , 2016, Pages 55-58

  Mengoli, Maria Cecilia ^a   Barbieri, Fausto ^a   Bertolini, Federica ^a   Tiseo, Marcello ^b   Rossi, Giulio ^a  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^b UNIVERSITY HOSPITAL OF PARMA   (Italy)

Author keywords

Adenocarcinoma; ALK; Crizotinib; K RAS; Lung; Resistance

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; ANAPLASTIC LYMPHOMA KINASE INHIBITOR; CISPLATIN; CRIZOTINIB; EPIDERMAL GROWTH FACTOR; K RAS PROTEIN; PEMETREXED; THYROID TRANSCRIPTION FACTOR 1; ANTINEOPLASTIC AGENT; KRAS PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR; PROTEIN P21; PROTEIN TYROSINE KINASE; PYRAZOLE DERIVATIVE; PYRIDINE DERIVATIVE;

ADULT; ANAMNESIS; ARTICLE; BONE METASTASIS; BRAIN METASTASIS; BRONCHUS BIOPSY; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; CANCER STAGING; CASE REPORT; CLINICAL ASSESSMENT; COMPUTER ASSISTED TOMOGRAPHY; COUGHING; DISEASE COURSE; DYSPHONIA; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION; GENE MUTATION; GENE REARRANGEMENT; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER METASTASIS; LUNG ADENOCARCINOMA; LUNG NODULE; MALE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MEDIASTINUM LYMPH NODE; MIDDLE AGED; MUTATIONAL ANALYSIS; NEUROIMAGING; PERITONEUM CANCER; PERSONAL EXPERIENCE; PRIORITY JOURNAL; SEIZURE; SMOKING; THORAX RADIOGRAPHY; TREATMENT RESPONSE; WEIGHT REDUCTION; ADENOCARCINOMA; ANTAGONISTS AND INHIBITORS; DNA MUTATIONAL ANALYSIS; DRUG RESISTANCE; FATALITY; GENE TRANSLOCATION; GENETICS; LUNG NEOPLASMS; MUTATION; TREATMENT OUTCOME; X-RAY COMPUTED TOMOGRAPHY;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS; DNA MUTATIONAL ANALYSIS; DRUG RESISTANCE, NEOPLASM; FATAL OUTCOME; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS P21(RAS); PYRAZOLES; PYRIDINES; RECEPTOR PROTEIN-TYROSINE KINASES; TOMOGRAPHY, X-RAY COMPUTED; TRANSLOCATION, GENETIC; TREATMENT OUTCOME;

EID: 84959421317     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2016.01.002     Document Type: Article

References (24)

1. Shaw A.T., Yeap B.Y., Mino-Kenudson M., et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J. Clin. Oncol. 2009, 27:4247-4253.
2. Gainor J.F., Varghese A.M., Ou S.H., et al. ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1683 patients with non-small cell lung cancer. Clin. Cancer Res. 2013, 19:4273-4281.
3. Kwak E.L., Bang Y.J., Camidge D.R., et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N. Engl. J. Med. 2010, 363:1693-1703.
4. Shaw A.T., Yeap B.Y., Solomon B.J., et al. Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. Lancet Oncol. 2011, 12:1004-1012.
5. Lovly C.M., Shaw A.T. Molecular pathways: resistance to kinase inhibitors and implications for therapeutic strategies. Clin. Cancer Res. 2014, 20:2249-2256.
6. Cameron L., Solomon B. Treatment of ALK-rearranged non-small cell lung cancer: recent progress and future directions. Drugs 2015, 75:1059-1070.
7. Doebele R.C., Pilling A.B., Aisner D.L., et al. Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer. Clin. Cancer Res. 2012, 18:1472-1482.
8. Rossing H.H., Grauslund M., Urbanska E.M., et al. Concomitant occurrence of EGFR (epidermal growth factor receptor) and KRAS (V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog) mutations in an ALK (anaplastic lymphoma kinase)-positive lung adenocarcinoma patient with acquired resistance to crizotinib: a case report. BMC Res. Notes 2013, 6:489.
9. Cabillic F., Gros A., Dugay F., et al. Parallel FISH and immunohistochemistry studies of ALK status in 3244 non-small-cell lung cancers reveal major discordances. J. Thorac. Oncol. 2014, 9:295-306.
10. Jürgens J., Engel-Riedel W., Prickartz A., et al. Combined point mutation in KRAS or EGFR genes and EML4-ALK translocation in lung cancer patients. Future Oncol. 2014, 10:529-532.
11. Campos-Gomez S., Lara-Guerra H., Routbort M.J., Lu X., Simon G.R. Lung adenocarcinoma with concurrent KRAS mutation and ALK rearrangement responding to crizotinib: case report. Int. J. Biol. Markers 2015, 30:e254-7.
12. Sahnane N., Frattini M., Bernasconi B., et al. EGFR and KRAS mutations in ALK-positive lung adenocarcinomas: biological and clinical effect. Clin. Lung Cancer 2015, Epub ahead of print. 10.1016/j.cllc.2015.08.001.
13. Ulivi P., Chiadini E., Dazzi C., et al. Frequency of concomitant EGFR, EML4-ALK or KRAS alterations in NSCLC patients and correlation with response to treatment. J. Thorac. Oncol. 2015, 10(Suppl. 9).
14. Stephen A.G., Esposito D., Bagni R.K., McCormick F. Dragging ras back in the ring. Cancer Cell 2014, 25:272-281.
15. Cargnelutti M., Corso S., Pergolizzi M., et al. Activation of RAS family members confers resistance to ROS1 targeting drugs. Oncotarget 2015, 6:5182-5194.
16. Bedard P.L., Hansen A.R., Ratain M.J., Siu L.L. Tumour heterogeneity in the clinic. Nature 2013, 501:355-364.
17. Cai W., Lin D., Wu C., et al. Intratumoral heterogeneity of ALK-rearranged and ALK/EGFR coaltered lung Aden ocarcinoma. J. Clin. Oncol. 2015, JCO.2014.58.8293, Epub ahead of print.
18. Misale S., Yaeger R., Hobor S., et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature 2012, 486:532-536.
19. Miranda C., Nucifora M., Molinari F., et al. KRAS and BRAF mutations predict primary resistance to imatinib in gastrointestinal stromal tumors. Clin. Cancer Res. 2012, 18:1769-1776.
20. Riely G.J., Marks J., Pao W. KRAS mutations in non-small cell lung cancer. Proc. Am. Thorac. Soc. 2009, 6:201-205.
21. Fiala O., Pesek M., Finek J., et al. The dominant role of G12C over other KRAS mutation types in the negative prediction of efficacy of epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Cancer Genet. 2013, 206:26-31.
22. Horn L., Pao W. EML4-ALK: honing in on a new target in non-small-cell lung cancer. J. Clin. Oncol. 2009, 27:4232-4235.
23. Ostrem J.M., Peters U., Sos M.L., Wells J.A., Shokat K.M. K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions. Nature 2013, 503:548-551.
24. Hrustanovic G., Olivas V., Pazarentzos E., et al. RAS-MAPK dependence underlies a rational polytherapy strategy in EML4-ALK-positive lung cancer. Nat. Med. 2015, 21:1038-1047.